11 Jan 2019 Governance

Leukaemia UK and Leuka have merged

We are delighted to announce that on 1 November Leuka and Leukaemia UK merged, bringing together two of the UK’s leading leukaemia and blood cancer charities to create one charity dedicated to innovative research and care for people affected by blood cancers. The two charities have joined forces under the name Leukaemia UK, uniting Leuka’s 37 years’ experience in ground-breaking medical research with Leukaemia UK’s four decades of pioneering care.

From research to care, the new charity will continue to put people affected by blood cancers at its heart. Together, Leukaemia UK aims to carry out even more world-class research and advances in care.

Leukaemia UK will be led jointly by Leuka’s CEO Olive Boles and Leukaemia UK’s CEO Angela Smith-Morgan. The charity’s new Chair of Trustees is Chris Corbin, current Chair of Leuka, who is supported by a Board including both Leuka and Leukaemia UK Trustees.

Related posts

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

8 September 2022

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…

Leukaemia UK and Leuka have merged

11 January 2019

Leukaemia UK and Leuka have merged

We are delighted to announce that on 1 November Leuka and Leukaemia UK merged

Leukaemia UK appoints new CEO

27 August 2020

Leukaemia UK appoints new CEO

The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.

First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights

12 June 2021

First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights

Dr Sandeep Potluri’s findings will contribute towards a better understanding, cure and treatments of leukaemia and blood cancers